Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selexipag in Children With Pulmonary Arterial Hypertension
DRKS00015024Phase 2Active, not recruiting
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 29
01
Overview
Phase 2, open-label, single-arm trial of selexipag in pulmonary arterial hypertension (PAH), Plexogenic Pulmonary Arteriopathy, Heritable Pulmonary Arterial Hypertension (HPAH) and 1 more, sponsored by Actelion Pharmaceuticals Ltd. Primary endpoints: Safety and tolerability of selexipag and Pharmacokinetics of selexipag. Started Jun 2021; status: active, not recruiting.
02
Drugs
selexipag
03
Conditions
pulmonary arterial hypertension (PAH)Plexogenic Pulmonary ArteriopathyHeritable Pulmonary Arterial Hypertension (HPAH)connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH)
Beyond the preview
Go deeper on DRKS00015024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00015024.